Nucleoside or nucleotide analogue inhibitors of viral replication almost act as chain terminators during DNA (DNA- and retroviruses) or RNA (RNA viruses) synthesis. Following intracellular phosphorylation, by viral and/or cellular kinases, the 5′-triphosphate metabolites (or 2′-diphosphate metabolites in the case of acyclic nucleoside phosphonate analogues) compete with the natural substrate in the DNA or RNA polymerization reaction. Obligatory chain terminators (e.g., acy clovir) do not offer the 3′-hydroxyl function at the riboside moiety of the molecule. Nucleoside analogues that possess a hydroxyl function at a position equivalent of the 3′-hydroxyl position may act as chain terminators if this hydroxyl group is confor-mationally constrained (e.g., ganciclovir) or sterically hindered to enter into a phos-phodiester linkage with the incoming nucleotide. In case that the 3′-hydroxylgroup is correctly positioned, chain elongation may be hampered through steric hindrance from neighboring substituents (e.g., 2′-C-methyl or 4′-azido nucleoside inhibitors of HCV replication). Here, we review the molecular mechanism of action and the clinical applications of the nucleosides and nucleotides acting as chain terminators. A further discussion of clinical applications in combination therapy can be found in Chap. 12.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Afdhal N, Godofsky E, Dienstag J, Rustgi V, Schick L, McEniry D, Zhou X-J, Chao G, Fang C, Fielman B, Myers M, Brown N (2004) Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. Hepatology 40:726A
Asif G, Hurwitz SJ, Obikhod A, Delinsky D, Narayanasamy J, Chu CK, McClure HM, Schinazi RF (2007) Pharmacokinetics of the anti-HIV agent 1-(β-D-dioxolane)thymine in Rhesus monkeys. Antimicrob Agents Chemother 51:2424–2429
Balzarini J, Schols D, Van Laethem K, De Clercq E, Hocková D, Masojidkova M, Holý A (2007) Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines. J Antimicrob Chemother 59:80–86
Beadle JR, Wan WB, Ciesla SL, Keith KA, Hartline C, Kern ER, Hostetler KY (2006) Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses. J Med Chem 49:2010–2015
Bonatti H, Aigner F, De Clercq E, Boesmueller C, Widschwendner A, Larcher C, Margreiter R, Schneeberger S (2007) Local administration of cidofovir for human papilloma virus associated skin lesions in transplant recipients. Transpl Int 20:238–246
Buller RM, Owens G, Schriewer J, Melman L, Beadle JR, Hostetler KY (2004) Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 318:474–481
Carroll SS, Tomassini JE, Bosserman M, Getty K, Stahlhut MW, Eldrup AB, Bhat B, Hall D, Simcoe AL, LaFemina R, Rutkowski CA, Wolanski B, Yang Z, Migliaccio G, De Francesco R, Kuo LC, MacCoss M, Olsen DB (2003) Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J Biol Chem 278:11979–11984
Carroll S, Koeplinger K, Burlein C, Stahlhut M, Vavrek M, MacCoss M, Hazuda D, Olsen D (2007) Nucleoside inhibitors of hepatitis C virus RNA polymerase: improved potency and liver targeting with 7-deaza-7-fluoro-2′-C-methyladenosine. In: Late breaker presentations. 20th international conference on antiviral research, Palm Springs, CA, USA, April 29-May 3, 2007, LB-01
Cihlar T, Ray AS, Boojamra CG, Zhang L, Hui H, Laflamme G, Vela JE, Grant D, Chen J, Myrick F, White KL, Gao Y, Lin KY, Douglas JL, Parkin NT, Carey A, Pakdaman R, Mackman RL (2008) Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phos-phonoamidate prodrug, GS-9131. Antimicrob Agents Chemother 52:655–665
Coelmont L, Paeshuyse J, Windisch MP, De Clercq E, Bartenschlager R, Neyts J (2006) Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2′-C-methylcytidine, the active com ponent of valopicitabine. Antimicrob Agents Chemother 50:3444–3446
D'Abramo CM, Cellai L, Götte M (2004) Excision of incorporated nucleotide analogue chain-terminators can diminish their inhibitory effects on viral RNA-dependent RNA polymerases. J Mol Biol 337:1–14
Dal Pozzo F, Andrei G, Lebeau I, Beadle JR, Hostetler KY, De Clercq E, Snoeck R (2007) In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA. Antiviral Res 75:52–57
De Clercq E (2002) Strategies in the design of antiviral drugs. Nat Rev Drug Discov 1:13–25
De Clercq E (2004a) Antiviral drugs in current clinical use. J Clin Virol 30:115–133
De Clercq E (2004b) Antivirals and antiviral strategies. Nat Rev Microbiol 2:704–720
De Clercq E (2006) From adefovir to AtriplaTM via tenofovir, VireadTM and TruvadaTM. Future Virol 1:709–715
De Clercq E (2007a) Acyclic nucleoside phosphonates: past, present and future. Bridging chem istry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem Pharmacol 73:911–922
De Clercq E (2007b) Anti-HIV drugs. Verh K Acad Geneesk Belg 44:81–104
De Clercq E (2007c) The design of drugs for HIV and HCV. Nat Rev Drug Discov 6:1001–1018
De Clercq E (2007d) The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. Antiviral Res 75:1–13
De Clercq E, Holý A (2005) Acyclic nucleoside phoshonates: a key class of antiviral drugs. Nat Rev Drug Discov 4:928–940
De Clercq E, Field HJ (2006) Antiviral prodrugs — the development of successful prodrug strategies for antiviral chemotherapy. Brit J Pharmacol 147:1–11
De Clercq E, Holý A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC (1986) A novel selective broad-spectrum anti-DNA virus agent. Nature 323:464–467
De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, Rosenberg I, Holý A (1987) Antivi ral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 8:261–272
De Clercq E, Andrei G, Snoeck R, De Bolle L, Naesens L, Degreve B, Balzarini J, Zhang Y, Schols D, Leyssen P, Ying C, Neyts J (2001) Acyclic/carbocyclic guanosine analogues as anti-herpesvirus agents. Nucleosides Nucleotides Nucleic Acids 20:271–285
De Clercq E, Andrei G, Balzarini J, Leyssen P, Naesens L, Neyts J, Pannecouque C, Snoeck R, Ying C, Hocková D, Holý A (2005) Antiviral potential of a new generation of acyclic nu cleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines. Nucle osides Nucleotides Nucleic Acids 24:331–341
Degrève B, De Clercq E, Balzarini J (1999) Bystander effect of purine nucleoside analogues in HSV-1 tk suicide gene therapy is superior to that of pyrimidine nucleoside analogues. Gene Ther 6:162–170
Deval J, Powdrill MH, D'Abramo CM, Cellai L, Götte M (2007) Pyrophosphorolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 51:2920–2928
Dutartre H, Bussetta C, Boretto J, Canard B (2006) General catalytic deficiency of hepatitis C virus RNA polymerase with an S28T mutation and mutually exclusive resistance towards 2′-modified nucleotide analogues. Antimicrob Agents Chemother 50:4161–4169
Eldrup AB, Allerson CR, Bennett CF, Bera S, Bhat B, Bhat N, Bosserman MR, Brooks J, Burlein C, Carroll SS, Cook PD, Getty KL, MacCoss M, McMasters DR, Olsen DB, Prakash TP, Prhavc M, Song Q, Tomassini JE, Xia J (2004) Structure-activity relationship of purine ribonu-cleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J Med Chem 47:2283–2295
Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ (1977) Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc Natl Acad Sci USA 74:5716–5720
Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovu dine, lamivudine, and efavirenz for HIV. N Engl J Med 354:251–260
Golankiewicz B, Ostrowski T, Andrei G, Snoeck R, De Clercq E (1994) Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity. J Med Chem 37:3187–3190
Golankiewicz B, Ostrowski T, Goslinski T, Januszczyk P, Zeidler J, Baranowski D, De Clercq E (2001) Fluorescent tricyclic analogues of acyclovir and ganciclovir. A structure-antiviral activ ity study. J Med Chem 44:4284–4287
Götte M (2006) Effects of nucleotides and nucleotide analogue inhibitors of HIV-1 reverse tran scriptase in a ratchet model of polymerase translocation. Curr Pharm Des 12:1867–1877
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Arterburn S, Xiong S, Currie G, Brosgart CL (2005) Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 352:2673–2681
Hartline CB, Gustin KM, Wan WB, Ciesla SL, Beadle JR, Hostetler KY, Kern ER (2005) Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis 191:396–399
Hirsch MS (2007) Entecavir surprise. N Engl J Med 356:2641–2643
Hostetler KY, Beadle JR, Trahan J, Aldern KA, Owens G, Schriewer J, Melman L, Buller RM (2007) Oral 1-O-octadecyl-2-O-benzyl-sn-glycero-3-cidofovir targets the lung and is effective against a lethal respiratory challenge with ectromelia virus in mice. Antiviral Res 73:212–218
Hu R, Li L, Degrève B, Dutschman GE, Lam W, Cheng YC (2005) Behavior of thymidylate kinase toward monophosphate metabolites and its role in the metabolism of 1-(2′-deoxy-2′-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (Clevudine) and 2′,3′-didehydro-2′, 3′-dideoxythymidine in cells. Antimicrob Agents Chemother 49:2044–2049
Kern ER, Hartline C, Harden E, Keith K, Rodriguez N, Beadle JR, Hostetler KY (2002) Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother 46:991–995
Kern ER, Bidanset DJ, Hartline CB, Yan Z, Zemlicka J, Quenelle DC (2004) Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infec tions. Antimicrob Agents Chemother 48:4745–4753
Kern ER, Kushner NL, Hartline CB, Williams-Aziz SL, Harden EA, Zhou S, Zemlicka J, Prichard MN (2005) In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication. Antimicrob Agents Chemother 49:1039–1045
Klumpp K, Lévêque V, Le Pogam S, Ma H, Jiang W-R, Kang H, Granycome C, Singer M, Laxton C, Hang JQ, Sarma K, Smith DB, Heindl D, Hobbs CJ, Merrett JH, Symons J, Cammack N, Martin JA, Devos R, Nájera I (2006) The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem 281:3793–3799
Klumpp K, Smith D, Brandl M, Alfredson T, Sarma K, Smith M, Nájera I, Jiang W-R, Le Pogam S, Lévêque V, Ma H, Tu Y, Chan R, Chen C-W, Wu X, Birudaraj R, Swallow S, Martin JA, Cammack N, Berns H, Fettner S, Ipe D, Mannino M, O'Mara E, Washington C, Roberts S, Cooksley G, Dore G, Shaw D, Blue DR Jr, Zahm F, Hill G (2007) Design and characterization of R1626, a prodrug of the HCV replication inhibitor R1479 (4′-azidocytidine) with enhanced oral bioavailability. Antiviral Res 74:A35 (abstract no 21)
Krečmerová M, Holý A, Pískala A, Masojídková M, Andrei G, Naesens L, Neyts J, Balzarini J, De Clercq E, Snoeck R (2007a) Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds. J Med Chem 50:1069–1077
Krečmerová M, Holý A, Pohl R, Masojídková M, Andrei G, Naesens L, Neyts J, Balzarini J, De Clercq E, Snoeck R (2007b) Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity. J Med Chem 50:5765–5772
Le Pogam S, Jiang W-R, Lévêque V, Rajyaguru S, Ma H, Kang H, Jiang S, Singer M, Ali S, Klumpp K, Smith D, Symons J, Cammack N, Nájera I (2006) In vitro selected Con1 subge-nomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 351:349–359
Lebeau I, Andrei G, Krečmerová M, De Clercq E, Holý A, Snoeck R (2007) Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains. Antimicrob Agents Chemother 51:2268–2273
Lee WA, He GX, Eisenberg E, Cihlar T, Swaminathan S, Mulato A, Cundy KC (2005) Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse tran scriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother 49:1898–1906
Lennerstrand J, Chu CK, Schinazi RF (2007) Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(βS-D-dioxolane)thymine triphosphate. Antimicrob Agents Chemother 51:2078–2084
Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, Colonno RJ (2002) Effi cacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 46:2525–2532
Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, Pawlotsky JM, Zoulim F (2004) Management of antiviral resistance in patients with chronic hepatitis B. Antiviral Ther 9:679–693
Ludmerer SW, Graham DJ, Boots E, Murray EM, Simcoe A, Markel EJ, Grobler JA, Flores OA, Olsen DB, Hazuda DJ, LaFemina RL (2005) Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimi crob Agents Chemother 49:2059–2069
Ma H, Jiang WR, Robledo N, Leveque V, Ali S, Lara-Jaime T, Masjedizadeh M, Smith DB, Cam mack N, Klumpp K, Symons J (2007) Characterization of the metabolic activation of hepati tis C virus nucleoside inhibitor beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and identification of a novel active 5′-triphosphate species. J Biol Chem 282:29812–29820
Magee WC, Hostetler KY, Evans DH (2005) Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob Agents Chemother 49:3153–3162
Magee WC, Aldern KA, Hostetler KY, Evans DH (2008) Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA poly merase when incorporated into the template strand. Antimicrob Agents Chemother 52:586–597
McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M, Xing S, Bhat S, Hale B, Hegarty R, Chong CR, Liu JQ, Siliciano RF, Thio CL (2007) The HBV drug entecavir — effects on HIV-1 replication and resistance. N Engl J Med Chem 356:2614–2621
Migliaccio G, Tomassini JE, Carroll SS, Tomei L, Altamura S, Bhat B, Bartholomew L, Bosser-man MR, Ceccacci A, Colwell LF, Cortese R, De Francesco R, Eldrup AB, Getty KL, Hou XS, LaFemina RL, Ludmerer SW, MacCoss M, McMasters DR, Stahlhut MW, Olsen DB, Hazuda DJ, Flores OA (2003) Characterization of resistance to non-obligate chain-terminating ribonu-cleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 278:49164–49170
Murakami E, Bao H, Ramesh M, McBrayer TR, Whitaker T, Micolochick Steuer HM, Schinazi RF, Stuyver LJ, Obikhod A, Otto MJ, Furman PA (2007) Mechanism of activation of beta-D-2′-deoxy-2′-fluoro-2′-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA poly merase. Antimicrob Agents Chemother 51:503–509
Murakami E, Niu C, Bao H, Micolochick Steuer HM, Whitaker T, Nachman T, Sofia MA, Wang P, Otto MJ, Furman PA (2008) The mechanism of action of beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine involves a second metabolic pathway leading to beta-D-2′-deoxy-2′-fluoro-2′-C-methyluridine 5′-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 52:458–464
Olsen DB, Eldrup AB, Bartholomew L, Bhat B, Bosserman MR, Ceccacci A, Colwell LF, Fay JF, Flores OA, Getty KL, Grobler JA, LaFemina RL, Markel EJ, Migliaccio G, Prhavc M, Stahlhut MW, Tomassini JE, MacCoss M, Hazuda DJ, Carroll SS (2004) A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob Agents Chemother 48:3944–3953
Ostrowski T, Golankiewicz B, De Clercq E, Balzarini J (2006) Synthesis and biological activ ity of tricyclic analogues of 9-{[cis-1′,2′-bis(hydroxymethyl)cycloprop-1′-yl]methyl}guanine. Bioorg Med Chem 14:3535–3542
Painter GR, Hostetler KY (2004) Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol 22:423–427
Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, Chen SS, McColl D, Ene-josa J, Toole JJ, Cheng AK (2006) Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: viro-logic, immunologic, and morphologic changes — a 96-week analysis. J Acquir Immune Defic Syndr 43:535–540
Quenelle DC, Collins DJ, Wan WB, Beadle JR, Hostetler KY, Kern ER (2004) Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob Agents Chemother 48:404–412
Quenelle DC, Collins DJ, Herror BP, Keith KA, Trahan J, Beadle JR, Hostetler KY, Kern ER (2007) Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonyl-methoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vac cinia virus infections in mice. Antimicrob Agents Chemother 51:3940–3947
Ray AS, Vela JE, Boojamra CG, Zhang L, Hui H, Callebaut C, Stray K, Lin KY, Gao Y, Mackman RL, Cihlar T (2008) Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent. Antimicrob Agents Chemother 52:648–654
Ruiz-Sancho A, Sheldon J, Soriano V (2007) Telbivudine: a new option for the treatment of chronic hepatitis B. Expert Opin Biol Ther 7:751–761
Stuyver LJ, McBrayer TR, Tharnish PM, Clark J, Hollecker L, Lostia S, Nachman T, Grier J, Bennett MA, Xie M-Y, Schinazi RF, Morrey JD, Julander JL, Furman PA, Otto MJ (2006) In hibition of hepatitis C replicon RNA synthesis by β-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antiviral Chem Chemother 17:79–87
Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK (1992) A protein kinase homo-logue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 359:85
Tomassini JE, Getty K, Stahlhut MW, Shim S, Bhat B, Eldrup AB, Prakash TP, Carroll SS, Flo res O, MacCoss M, McMasters DR, Migliaccio G, Olsen DB (2005) Inhibitory effect of 2′-substituted nucleosides on hepatitis C virus replication correlates with metabolic properties in replicon cells. Antimicrob Agents Chemother 49:2050–2058
Tomei L, Altamura S, Paonessa G, De Francesco R, Migliaccio G (2005) HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase. Antiviral Chem Chemother 16:225–245
Toniutto P, Fabris C, Bitetto D, Fornasiere E, Rapetti R, Pirisi M (2007) Valopicitabine dihy-drochloride: a specific polymerase inhibitor of hepatitis C virus. Curr Opin Investig Drugs 8:150–158
Tuske S, Sarafianos SG, Clark AD, Ding J, Naeger LK, White KL, Miller MD, Gibbs CS, Boyer PL, Clark P, Wang G, Gaffney BL, Jones RA, Jerina DM, Hughes SH, Arnold E (2004) Struc tures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug teno-fovir. Nat Struct Mol Biol 11:469–474
Wang J, Jin Y, Rapp KL, Bennett M, Schinazi RF, Chu CK (2005) Synthesis, antiviral activity, and mechanism of drug resistance of D- and L-2′,3′-didehydro-2′,3′-dideoxy-2′-fluorocarbocyclic nucleosides. J Med Chem 48:3736–3748
Wang J, Jin Y, Rapp KL, Schinazi RF, Chu CK (2007) D- and L-2′,3′-didehydro-2′,3′-dideoxy-3′-fluoro-carbocyclic nucleosides: synthesis, anti-HIV activity and mechanism of resistance. J Med Chem 50:1828–1839
Wyles DL, Schooley RT, Kaihara KA, Beadle JR, Hostetler KY (2008) Anti-hepatitis C virus repli-con activity of alkoxyalkyl esters of (S)-HPMPA and other acyclic nucleoside phosphonates. In: Abstracts of the 21st international conference on antiviral research, Montreal, QC, Canada, 13–17 April 2008. Antiviral Res 78:A21, no 15
Xiong X, Smith JL, Chen MS (1997) Effect of incorporation of cidofovir into DNA by hu man cytomegalovirus DNA polymerase on DNA elongation. Antimicrob Agents Chemother 41:594–599
Zhou S, Breitenbach JM, Borysko KZ, Drach JC, Kern ER, Gullen E, Cheng YC, Zemlicka J (2004) Synthesis and antiviral activity of (Z)- and (E)-2,2-[bis(hydroxymethyl) cyclopropylidene]methylpurines and -pyrimidines: second-generation methylenecyclopropane analogues of nucleosides. J Med Chem 47:566–575
Zoulim F (2006) Entecavir: a new treatment option for chronic hepatitis B. J Clin Virol 36:8–12
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
De Clercq, E., Neyts, J. (2009). Antiviral Agents Acting as DNA or RNA Chain Terminators. In: Kräusslich, HG., Bartenschlager, R. (eds) Antiviral Strategies. Handbook of Experimental Pharmacology, vol 189. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-79086-0_3
Download citation
DOI: https://doi.org/10.1007/978-3-540-79086-0_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-79085-3
Online ISBN: 978-3-540-79086-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)